Ganoderma Spores Modulate the Gut-Brain Axis

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Depression, Thyroid Cancer

In brief

This study aims to investigate whether Sporoderm-removed Ganoderma lucidum spore powder (RGLS) ameliorates depression in thyroid cancer patients through gut-brain axis modulation, and to elucidate the underlying microbial and metabolic mechanisms. This 3-month randomized, double-blind, placebo-controlled trial will enroll 300 postoperative papillary thyroid carcinoma patients with depressive symptoms (HAMD-24 ≥ 8). Participants will be randomly assigned(2 : 1) to receive RGLS (4 g/day) or matched placebo.

Key facts

Study ID
NCT07524777
Run by
Ling Zhiqiang
People needed
300
Starts
2026-04-11
Expected to finish
2026-08-31
Last updated by the study team
2026-05-12

Who can join

Age: 18 and older, up to 80. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.